Antiviral activity of the drug based on the complex of single-stranded high-polymer RNA against the rabies virus in vitro

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Rabies is an infectious disease with absolute mortality. Currently, there are no effective drugs and treatment regimens for people with signs of rabies. The only strategy for post-exposure rabies prevention is vaccination and administration of rabies immunoglobulin. At the same time, the search for new treatment and prevention regimens for the disease remains relevant, which is why the development and study of antiviral drugs effective against the rabies virus is relevant.

Objective of the study. To study the antiviral activity of a drug based on single-stranded high-polymer RNA of Sacharomyces cerevisiae, which has previously shown antiviral activity against other pathogens of viral infections.

Material and methods. The work investigated the effect of the drug based on single-stranded high-polymer RNA of S. cerevisiae "Amphievovir" on the level of reproduction of the attenuated rabies virus strain "Saratov" on the Vero cell culture model.

Results. The studied drug in the concentration range from 10 to 20 μg/ml and added to the cell culture no later than 24 hours after infection reduces the titer of the virus by 24.6 to 36.2% compared to the control group. Adding the drug to the infected cell culture later than 24 hours reduces its antiviral effect.

Conclusions. The studied drug based on single-stranded high-polymer RNA of S. cerevisiae has antiviral activity against the rabies virus in vitro. The results allow us to justify further study of post-exposure rabies prophylaxis regimens using drugs based on immunostimulating and immunomodulatory RNA.

Full Text

Restricted Access

About the authors

S. V. Generalov

Russian Anti-Plague Research Institute «Microbe» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Author for correspondence.
Email: svgeneraloff@gmail.com
ORCID iD: 0000-0003-1461-5383
SPIN-code: 4130-2475

Ph.D. (Biol.), Leading Research Scientist, Laboratory of Preventive Immunoglobulins

Russian Federation, Universitetskaya St., 46, Saratov, 410005

D. A. Perevoznikov

Russian Anti-Plague Research Institute «Microbe» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: rusrapi@microbe.ru

Master's Student, Laboratory Assistant-Researcher, Laboratory of Preventive Immunoglobulins

Russian Federation, Universitetskaya St., 46, Saratov, 410005

Е. G. Abramova

Russian Anti-Plague Research Institute «Microbe» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; Saratov State University of Genetics, Biotechnology and Engineering named after N.I. Vavilov

Email: rusrapi@microbe.ru
ORCID iD: 0000-0002-8798-1547
SPIN-code: 3382-3399

Dr.Sc. (Biol.), Head of the Laboratory of Preventive Immunoglobulins

Russian Federation, Universitetskaya St., 46, Saratov, 410005; Pyotr Stolypin Avenue, building 4, building 3, Saratov, 410012

A. K. Nikiforov

Russian Anti-Plague Research Institute «Microbe» of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing; Saratov State University of Genetics, Biotechnology and Engineering named after N.I. Vavilov

Email: rusrapi@microbe.ru
ORCID iD: 0000-0002-1130-3504
SPIN-code: 3202-3979

Dr.Sc. (Biol.), Professor, Deputy Director for Experimental and Production Work

Russian Federation, Universitetskaya St., 46, Saratov, 410005; Pyotr Stolypin Avenue, building 4, building 3, Saratov, 410012

A. A. Spitsyn

Limited Liability Company «SPA Evolution of Nature»

Email: evoprirody@yandex.ru
ORCID iD: 0009-0005-4900-826X

Chief Research Scientist

Russian Federation, Voskhod St. 20/1, room 1.2, Novosibirsk, 630102

T. V. Potupchik

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of the Russian Federation

Email: potupchik_tatyana@mail.ru
ORCID iD: 0000-0003-1133-4447
SPIN-code: 8353-3513

Ph.D. (Med.), Associate Professor of the Department of Pharmacology and Clinical Pharmacology with a postgraduate course

Russian Federation, 1, Partizan Zheleznyak str., Krasnoyarsk, 660022

Е. M. Shenderovich

The Gamaleya National Center of Epidemiology and Microbiology

Email: rusrapi@microbe.ru
ORCID iD: 0009-0003-3382-1411

Laboratory Research Assistant, Laboratory of Indication and Ultrastructural Analysis of Microorganisms

Russian Federation, Gamaleyi street, building 18, Moscow, 123098

References

  1. Zheng J., Sui B., Zhao L. Rabies lyssavirus. Veterinary Virology of Domestic and Pet Animals. Cham: Springer Nature Switzerland, 2025; 1–19.
  2. WHO Expert Consultation on Rabies, third report. Geneva: World Health Organization; 2018 (WHO Technical Report Series, No. 1012). 195
  3. Lacy M., Phasuk N., Scholand S.J. Human Rabies Treatment – From Palliation to Promise. Viruses. 2024; 16(1):160. doi: 10.3390/v16010160
  4. Kovalev N.A., Buchukuri D.V. Izuchenie beshenstva i razrabotka sredstv i sposobov ego profilaktiki v Belarusi. Vescі Nacyyanal'naj akademіі navuk Belarusі. Seryya agrarnyh navuk. 2014; 4: 96–102. (In Russ.).
  5. Buchukuri D.V., Kovalev N.A., Lomako Yu.V. i dr. Vakcinosoderzhashchaya bezblisternaya primanka dlya peroral'noj immunizacii plotoyadnyh zhivotnyh protiv beshenstva. Izvestiya Nacional'noj akademii nauk Belarusi. Seriya agrarnyh nauk. 2019; 57(3): 334–343. (In Russ.).
  6. Yamada K., Noguchi K., Kimitsuki K., et al. Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis. Antiviral Res. 2019; 172: 104641. doi: 10.1016/j.antiviral.2019.104641.
  7. Wu J., Cao S., Lei S., et al. Clofazimine: a promising inhibitor of rabies virus. front pharmacol. 2021; 12: 598241. doi: 10.3389/fphar.2021.598241.
  8. Scott T.P., Nel L.H. Rabies prophylactic and treatment options: an in vitro study of sirna- and aptamer-based therapeutics. Viruses. 2021; 13(5): 881. doi: 10.3390/v13050881
  9. Brandão P.E., Castilho J.G., Fahl W., et al. Short-interfering RNAs as antivirals against rabies. Braz. J. Infect. Dis. 2007; 11(2): 224–225. doi: 10.1590/s1413-86702007000200011.
  10. Ermolaev V.V., Shimina G.G., Alikin Yu.S. i dr. Novye preparaty immunomodulyatorov na osnove RNK dlya lecheniya virusnyh infekcij. Innovacii i prodovol'stvennaya bezopasnost'. 2023; 4: 78–89. DOI.org/10.31677/2311-0651-2023-42-4-78-89. (In Russ.).
  11. Danilenko E.D., Belkina A.O., Sysoeva G.M. Sozdanie lekarstvennyh preparatov na osnove vysokopolimernyh dvuspiral'nyh RNK dlya protivovirusnoj i protivoopuholevoj terapii. Biomedicinskaya himiya. 2019; 65(4): 277–293. (In Russ.).
  12. Starkov F.I., Shalin V.V., Mironov V.S., Mironov A.V. Miluokskij protokol – ot idei do realizacii. Medicinskij vestnik Yuga Rossii. 2023; 14(3): 59–65. doi: 10.21886/2219-8075-2023-14-3-59-65. (In Russ.).
  13. Ignat'ev G.M., Shustova E.Yu., Rogozhina E.A. i dr. Protivovirusnaya aktivnost' lekarstvennogo preparata na osnove RNK dvuspiral'noj natrievoj soli v otnoshenii SARS-CoV-2 in vitro. BIOpreparaty. Profilaktika, diagnostika, lechenie. 2023; 23(3): 290–299. doi: 10.30895/2221-996X-2023-23-3-290-299. (In Russ.).
  14. Yamkovaya T.V., Mazurkova N.A., Zagrebel'nyj S.N. i dr. Sposob lecheniya ospy. Patent № 2480219. opubl. 27.04.2013. Byul. №12. (In Russ.).
  15. Yamkovaya T.V., Glotova T.I., Kolesnikova O.P. i dr. Legko pronikayushchij cherez biologicheskie membrany mylkij amfifil'nyj induktor interferona γ-perspektivnyj preparat dlya lecheniya gepatita s cheloveka. Sibirskij nauchnyj medicinskij zhurnal. 2014. 34(1): 15–20. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Neutralizing effect of amphivoir on rabies virus (number of experiments for each group n=3)

Download (88KB)
Indexing metadata
3. Fig. 2. Study of antiviral activity on infected cell culture (number of experiments for each group n=3)

Download (109KB)
Indexing metadata
4. Fig. 3. Study of the antiviral effect on the infected cell culture depending on the time of application (number of experiments for each group n=3)

Download (91KB)
Indexing metadata

Copyright (c) 2025 Russkiy Vrach Publishing House